AMHRII expression and Antibody-Drug Conjugate preclinical data suggest potential broader applications for anti-AMHRII-based therapy
Paris and Toulouse, France, April 12, 2018 – GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting AMHRII for the treatment of cancer, today announces the presentation of two posters on its AMHRII program at the upcoming American Association for Cancer Research (AACR) annual meeting, taking place from April 14 to 18 in Chicago, USA.
The results of extensive investigations show AMHRII expression in a majority of tumor samples in a wide range of non-gynecological tumors such as colorectal and lung cancers, hepatocarcinoma or renal cell carcinoma. Moreover internalization capabilities and selective distribution of the target have been utilized to design a first AMHR2 based ADC approach.
The presentation details are as follows:
- Title: Anti-Müllerian Hormone type II Receptor (AMHRII) found expressed in human non-gynecological solid tumors, suggesting potential broader applications for anti-AMHRII-based therapy
o Abstract number: 774
o Date and time: April 15, 2018, 1pm – 5pm (CT)
o Session category/title: Experimental and Molecular Therapeutics
o Location: Section 36
- Title: Anti-Müllerian hormone type II receptor (AMHRII), a cancer target for GM103, a novel antibody-drug conjugate (ADC)
o Abstract number: 1779
o Date and time: April 16, 2018, 8am – 12pm (CT)
o Session category/title: Therapeutic Antibodies, including Engineered
o Location: Section 34
The studies were performed with GamaMabs’ partners, including the Curie Institute (Paris, France), the Gustave Roussy Institute (Villejuif, France), Massachusetts General Hospitals (Boston, USA), the Léon Bérard Cancer Center (Lyon, France), Nantes University Hospital (France), the Montpellier Cancer Research Institute (France), Abzena (UK) and the Helsinki University Hospital (Finland).
“We are happy to be able to share such groundbreaking data on AMHRII expression, unveiling its potential as a novel target in a wide range of solid tumors,” said Jean-François Prost, VP R&D at GamaMabs. “The results with GM103 clearly show, as a proof of concept, that AMHRII is also a suitable target for treating AMHRII-positive solid tumors with an ADC.”
“We are committed to expanding our development plans beyond gynecological cancers, in particular for our lead program GM102,” said Stéphane Degove, CEO at GamaMabs.
A copy of the above referenced abstracts can be viewed online through the AACR meeting website. Following the presentation, the data presented will be available on the Publications page of GamaMabs’ website.
About GamaMabs Pharma
GamaMabs Pharma, a French immuno-oncology biotechnology company, is a leader in the development of optimized antibodies targeting AMHRII for the treatment of cancer.
Gamamabs’ first-in-class proprietary therapeutic monoclonal antibodies promise to have a broad commercial potential in cancer. GamaMabs Pharma’s lead project is the first-inclass monoclonal antibody (mAb) GM102. This antibody, which targets the anti-Müllerian human receptor II (AMHRII/MISR2), entered a first clinical trial in gynecological cancers in H1 2016. Initial results will be published at the 2018 ASCO annual meeting. The company develops low-fucose EMABling® antibodies (license granted by LFB) with increased tumor cell killing properties through a breakthrough activation of immune system cells. GamaMabs also has a licensing agreement with MedImmune (USA) to develop an Antibody Drug Conjugate targeting cancer.